×
Amgen Inventory 2010-2025 | AMGN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Amgen inventory for the quarter ending March 31, 2025 was
$6.729B
, a
22.87% decline
year-over-year.
Amgen inventory for 2024 was
$6.998B
, a
26.48% decline
from 2023.
Amgen inventory for 2023 was
$9.518B
, a
93.06% increase
from 2022.
Amgen inventory for 2022 was
$4.93B
, a
20.66% increase
from 2021.
View More
Amgen Inventory 2010-2025 | AMGN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Amgen inventory for 2024 was
$6.998B
, a
26.48% decline
from 2023.
Amgen inventory for 2023 was
$9.518B
, a
93.06% increase
from 2022.
Amgen inventory for 2022 was
$4.93B
, a
20.66% increase
from 2021.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$209.6B
Gilead Sciences (GILD)
$130.2B
Vertex Pharmaceuticals (VRTX)
$125.6B
Bristol Myers Squibb (BMY)
$100.2B
CSL (CSLLY)
$74.3B
GSK (GSK)
$74.1B
Regeneron Pharmaceuticals (REGN)
$61.6B
Argenex SE (ARGX)
$36.2B
Alnylam Pharmaceuticals (ALNY)
$30.5B
BioNTech SE (BNTX)
$23.7B
BeiGene (ONC)
$22.8B
Biogen (BIIB)
$17.4B
Genmab (GMAB)
$13.3B
Genmab (GNMSF)
$13.3B
Insmed (INSM)
$13.2B
BioMarin Pharmaceutical (BMRN)
$11.3B
Illumina (ILMN)
$11.3B
Incyte (INCY)
$11.3B
Ascendis Pharma (ASND)
$10.1B
Exelixis (EXEL)
$10B
Swedish Orphan Biovitrum (BIOVF)
$9.6B
Moderna (MRNA)
$9.6B
QIAGEN (QGEN)
$9B
Exact Sciences (EXAS)
$7.7B
Bio-Techne Corp (TECH)
$7.6B
Repligen (RGEN)
$7.3B
Halozyme Therapeutics (HALO)
$7.3B
Roivant Sciences (ROIV)
$7.2B
Revolution Medicines (RVMD)
$6.8B
Bio-Rad Laboratories (BIO.B)
$6.3B